Catalent, Inc. has received $0.24 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $0.22 while the top line estimate is $0.25 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -32.38%.
Catalent, Inc. results fell short with a surprise EPS of -7.69% or $-0.01. The Actual EPS was $0.12 compared to the Estimated EPS of $0.13 during its most recent quarterly earnings.
Catalent, Inc. has a Price to Earnings ratio of 22.15 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 5.31. For the Most Recent Fiscal Year, Catalent, Inc. has a price to cash ratio of 11.2. For the Trailing twelve month period, company showed a Net Profit Margin of 5.53% and Return on Equity of the stock is 24.14%.
In the last quarter, Catalent, Inc. reported Annual Earnings of $0.12. Based on the filings, last years Annual Earnings was, $1.16. In the last Quarter, CTLT reported a surprise Earnings per Share of -7.69% . The consensus estimate for current quarter is $0.24 and for the current fiscal year, the estimate is $1.3. For the Next fiscal year, the estimate is $1.48 based on the consensus.
Catalent, Inc. (NYSE:CTLT) : On Tuesday heightened volatility was witnessed in Catalent, Inc. (NYSE:CTLT) which led to swings in the share price. The stock opened for trading at $25.89 and hit $26.94 on the upside , eventually ending the session at $26.76, with a gain of 2.37% or 0.62 points. The heightened volatility saw the trading volume jump to 1,642,950 shares. The 52-week high of the share price is $32.24 and the company has a market cap of $3,338 million. The 52-week low of the share price is at $18.92 .
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey.